Cargando…

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review

Anti-PD-(L)1 therapies yield a disappointing response rate of 15% across soft-tissue sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and TILs in their tumor microenvironment are variable, and this heterogeneity correlates to histotype. Tumors with a richer CD8+ T ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roulleaux Dugage, Matthieu, Nassif, Elise F., Italiano, Antoine, Bahleda, Rastislav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678134/ https://www.ncbi.nlm.nih.gov/pubmed/34925348 http://dx.doi.org/10.3389/fimmu.2021.775761

Ejemplares similares

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy
por: Crombé, Amandine, et al.
Publicado: (2022)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma
por: Gu, Hui-Yun, et al.
Publicado: (2022)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

m6A-related metabolism molecular classification with distinct prognosis and immunotherapy response in soft tissue sarcoma
por: Huang, Zhen-Dong, et al.
Publicado: (2022)

The Landscape of Immunotherapy for Retroperitoneal Sarcoma
por: Gingrich, Alicia A., et al.
Publicado: (2023)

Immunotherapy for Bone and Soft Tissue Sarcomas
por: Uehara, Takenori, et al.
Publicado: (2015)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas
por: Seong, Gyuhee, et al.
Publicado: (2023)

Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes
por: Yamada, Yosuke, et al.
Publicado: (2020)

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
por: Ducimetière, Françoise, et al.
Publicado: (2011)

Gene expression-based dissection of inter-histotypes, intra-histotype and intra-tumor heterogeneity in pediatric tumors
por: Ciceri, Sara, et al.
Publicado: (2022)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
por: Albertsmeier, Markus, et al.
Publicado: (2022)

Comprehensive Profiling Reveals Prognostic and Immunogenic Characteristics of Necroptosis in Soft Tissue Sarcomas
por: Qi, Lin, et al.
Publicado: (2022)

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
por: Li, Yong, et al.
Publicado: (2022)

Ovarian carcinoma histotype in Lynch syndrome
por: Gilks, C. Blake, et al.
Publicado: (2017)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
por: Raj, Shailaja, et al.
Publicado: (2018)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
por: Kerrison, William G. J., et al.
Publicado: (2022)

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
por: Panagi, Myrofora, et al.
Publicado: (2022)

Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies
por: Caruso, Chiara, et al.
Publicado: (2020)

ASO Author Reflections: Towards Patient-Tailored Management of Extremity Soft Tissue Sarcoma
por: Acem, I., et al.
Publicado: (2021)

Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
por: Kantidakis, Georgios, et al.
Publicado: (2022)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
por: Ben-Ami, Eytan, et al.
Publicado: (2020)

Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx
por: Sun, Bao, et al.
Publicado: (2023)

m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma
por: Huang, Zhen-Dong, et al.
Publicado: (2021)

Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model
por: Marritt, Kayla L., et al.
Publicado: (2023)

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas
por: Monga, Varun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_occd10lakg3a9dc1s9519m14ns